v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 221,184 $ 189,447
Selling, general and administrative 98,735 72,180
Total operating expenses 319,919 261,627
Loss from operations (319,919) (261,627)
Other income (expense):    
Research and development incentives 1,604 1,773
Investment income 13,625 21,120
Interest expense on finance lease liability (2,063) (2,118)
Interest expense on debt obligations (6,796) (5,775)
Other expense (942) (202)
Total other income, net 5,428 14,798
Loss before income taxes (314,491) (246,829)
Income tax (benefit) provision (551) 468
Net loss $ (313,940) $ (247,297)
Net loss per common share, basic (in dollars per share) $ (3.38) $ (3.07)
Net loss per common share, diluted (in dollars per share) $ (3.38) $ (3.07)
Weighted average common shares outstanding, basic (in shares) 92,803,711 80,564,147
Weighted average common shares outstanding, diluted (in shares) 92,803,711 80,564,147